Group One Trading
BBC icon

Group One Trading’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Group One Trading’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8K Hold
300
– – ﹤0.01% 6151
2026
Q1 		$12.5K Sell
300
-1,271
-81% -$52K ﹤0.01% 6238
2025
Q4 		$60.6K Buy
+1,571
New +$53.4K ﹤0.01% 5434

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Group One Trading's BBC Position: Q2 2026 in Review

Group One Trading held its Virtus Biotech Clinical Trials ETF (BBC) position steady in Q2 2026 at 300 shares worth $15.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6151.

Group One Trading first reported a position in BBC in Q4 2025 and has held it in 3 quarters since. The position peaked at $60.6K in Q4 2025. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

  • Group One Trading held 300 shares of Virtus Biotech Clinical Trials ETF worth $15.8K as of Q2 2026.
  • Group One Trading left its Virtus Biotech Clinical Trials ETF share count unchanged in Q2 2026.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6151 holding.
  • Group One Trading first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2025 and has held it in 3 quarters since.
  • Group One Trading's Virtus Biotech Clinical Trials ETF position peaked at $60.6K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.